^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | MEN1611 (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Men1611 is a pi3k a/ß selective and d sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models
Published date:
11/17/2020
Excerpt:
MEN1611 monotherapy showed a significant tumor volume inhibition in a PTEN-null breast cancer PDX model.
